08:19 AM EDT, 10/28/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that results from a phase 3 study of Tremfya as a treatment for Crohn's disease showed high remission rates among tested patients.

The first 12 weeks of the trial where Tremfya was administered subcutaneously showed that 56.1% of treated patients achieved clinical remission, J&J said.

After 48 weeks, the rates of clinical remission were more than 60% in two different doses, the company said.

Tremfya's safety profile was consistent with previous studies, J&J said.